Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
Related Questions
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
